GCM
AERI

Graham Capital Management’s Aerie Pharmaceuticals AERI Stock Holding History

Graham Capital Management’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-50,017
Closed -$375K – 1395
2022
Q2 		$375K Buy
+50,017
New +$353K 0.02% 758
2022
Q1 		– Sell
-33,168
Closed -$232K – 1066
2021
Q4 		$232K Buy
+33,168
New +$347K 0.01% 412

Other funds holding AERI

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Graham Capital Management's AERI Position: Q3 2022 in Review

Graham Capital Management sold out of Aerie Pharmaceuticals (AERI) in Q3 2022, closing a stake of 50,017 shares — an estimated $375K sold.

Graham Capital Management first reported a position in AERI in Q4 2021 and held it in 2 quarters. The position peaked at $375K in Q2 2022. 156 funds tracked by Wall St. Rank hold AERI as of Q3 2022.

  • Graham Capital Management reported no remaining Aerie Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Graham Capital Management sold 50,017 Aerie Pharmaceuticals shares in Q3 2022, an estimated $375K.
  • Graham Capital Management first reported a position in Aerie Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Graham Capital Management's Aerie Pharmaceuticals position peaked at $375K in Q2 2022.
  • 156 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2022.

Based on Graham Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.